In vivo, RMC-6291(200 mg/kg) resulted in a 68% Objective Response Rate (ORR), while the Adagrasib (100 mg/kg) treatment resulted in 43%, in a range of NSCLC KRAS G12C-mutated cancers. Here, KRAS is linked to non-small cell lung carcinoma.